Joflupaan (123i) Rotop

Ioflupane, the active ingredient in Joflupaan (123i) Rotop, is a radiopharmaceutical presented as an injectable solution for intravenous use. It is used to evaluate dopaminergic neuron integrity in patients with suspected Parkinsonian syndromes and related neurological disorders.

GNH USA supplies Joflupaan (123i) Rotop as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, clinics and diagnostic centres worldwide.

Joflupaan (Ioflupane) is employed in neurological imaging to assess the dopaminergic system in several conditions.

Parkinsonian syndromes: enables visualization of dopamine transporter loss to support diagnosis. Parkinson's disease differential diagnosis: helps distinguish Parkinson's disease from other movement disorders. Dementia with Lewy bodies: assists in detecting dopaminergic deficits characteristic of Lewy body disease.

Adverse reactions may occur following administration of Ioflupane.

Common Side Effects: - Nausea or mild gastrointestinal discomfort. - Transient headache. - Injection‑site pain or irritation. - Dizziness or light‑headedness. - Temporary hypotension.

Serious or Rare Side Effects: - Allergic reactions, including rash or urticaria. - Anaphylaxis or severe hypersensitivity. - Significant hypotension requiring medical intervention. - Radiation‑induced tissue injury at the injection site. - Severe arrhythmias or cardiac events.

Prior to use, clinicians should consider several safety measures.

Assess renal function: ensure adequate clearance of the radiopharmaceutical. Evaluate pregnancy status: avoid use unless benefits outweigh potential fetal risk. Review concomitant dopamine‑affecting drugs: they may alter imaging results. Confirm appropriate imaging facility: requires SPECT equipment and radiation safety protocols. Monitor for allergic reactions during and after injection. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ioflupane may interact with other agents that influence dopamine pathways or radiopharmaceutical distribution.

Major Interactions (Avoid): - Co‑administration of other dopamine‑targeting radiotracers: can interfere with image interpretation. - High‑dose dopamine agonists or levodopa taken shortly before imaging: may block transporter binding.

Moderate Interactions (Monitor Closely): - Antipsychotics that block dopamine transporters: may reduce tracer uptake. - MAO‑B inhibitors: potential alteration of tracer kinetics. - Antihypertensive agents: may exacerbate transient hypotension. - Medications affecting cerebral blood flow (e.g., vasodilators): could modify tracer distribution.